Ikeguchi M, Makino M, Kaibara N
Department of Surgery I, Faculty of Medicine, Tottori University, 36-1 Nishi-cho, Yonago 683-8504, Japan.
Anticancer Res. 2000 Sep-Oct;20(5C):3833-7.
Familial adenomatous polyposis (FAP) is a dominantly inherited disorder and it is difficult to know when polyps change to carcinoma. In this study, we retrospectively evaluated whether telomerase activity and p53 gene mutations are useful parameters for detecting malignant changes in polyps in patients with FAP.
Twenty-one tissue samples (carcinoma: 5, large polyp: 8, and small polyp: 8) were obtained from 8 patients with FAP. Colorectal carcinomas were detected in 5 patients. As a control, 68 colorectal carcinomas and 11 adenomatous polyps with synchronous colorectal carcinoma from 68 patients and 8 polyps from 8 patients without colorectal carcinoma were obtained. The telomeric repeat amplification protocol (TRAP) assay was used for the detection of telomerase activity. In 21 samples from FAP patients, mutations of exon 5 to 8 in the p53 gene were analyzed by the polymerase chain reaction-single strand conformation polymorphism (PCR-SSCP) method.
In 5 patients with FAP who had carcinomas in their colon and rectum, all the samples (carcinomas, large polyps and small polyps) showed telomerase activity. In contrast, in the 3 patients with FAP who had no carcinomas, telomerase activity was not detected in either the large or small polyps. Telomerase activity was detected in 51 out of 68 control colorectal carcinomas (75%) and in 6 out of 19 adenomas (32%). The p53 gene mutation was detected in only 2 carcinomas from 2 patients with FAP and was not detected in any large and small polyps.
These findings suggest that telomerase is activated before the occurrence of the p53 gene mutation. In FAP, genetic changes associated with the development of colonic adenoma into carcinoma might activate telomerase and such genetic changes might occur in whole polyps of the colon and rectum.
家族性腺瘤性息肉病(FAP)是一种显性遗传性疾病,息肉何时转变为癌很难知晓。在本研究中,我们回顾性评估端粒酶活性和p53基因突变是否为检测FAP患者息肉恶变的有用参数。
从8例FAP患者获取21份组织样本(癌组织:5份,大息肉:8份,小息肉:8份)。5例患者检测到结直肠癌。作为对照,从68例患者获取68份结直肠癌组织和11份伴有同步结直肠癌的腺瘤性息肉,从8例无结直肠癌患者获取8份息肉。采用端粒重复序列扩增法(TRAP)检测端粒酶活性。对FAP患者的21份样本,采用聚合酶链反应-单链构象多态性(PCR-SSCP)法分析p53基因第5至8外显子的突变情况。
5例患有结肠和直肠癌的FAP患者,所有样本(癌组织、大息肉和小息肉)均显示端粒酶活性。相反,3例无癌的FAP患者,其大息肉和小息肉均未检测到端粒酶活性。68份对照结直肠癌组织中有51份(75%)检测到端粒酶活性,19份腺瘤中有6份(32%)检测到端粒酶活性。仅在2例FAP患者的2份癌组织中检测到p53基因突变,在任何大息肉和小息肉中均未检测到。
这些发现提示端粒酶在p53基因突变发生之前被激活。在FAP中,与结肠腺瘤发展为癌相关的基因改变可能激活端粒酶,且这种基因改变可能发生在结肠和直肠的整个息肉中。